Issue 4/2023
Content (13 Articles)
PARP Inhibitors in Ovarian Cancer: A Review
David M. O’Malley, Thomas C. Krivak, Nashwa Kabil, Jiefen Munley, Kathleen N. Moore
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
Chao-Hua Chiu, Meng-Chih Lin, Yu-Feng Wei, Gee-Chen Chang, Wu-Chou Su, Te-Chun Hsia, Jian Su, Anne Kuei-Fang Wang, Min-Hua Jen, Tarun Puri, Jin-Yuan Shih
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
Todd M. Bauer, Kathleen N. Moore, Janet S. Rader, Fiona Simpkins, Alain C. Mita, J. Thaddeus Beck, Lowell Hart, Quincy Chu, Amit Oza, Anna V. Tinker, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David Spigel, Siqing Fu
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA
David Elsea, Dominic Muston, Lin Fan, Adela Mihai, Yang Meng, Adam Kasle, Matthew Monberg
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer
Angela DeMichele, Nicholas Robert, Connie Chen, Sindy Kim, Zhe Zhang, Dongrui Ray Lu, Kathleen M. Aguilar, Yunfei Wang, Benjamin Li, Sebastian Schneeweiss, Jeremy A. Rassen, Michael Gaffney, Lynn McRoy
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni, Francesco Massari, Zin W. Myint, Roberto Iacovelli, Martin Pichler, Umberto Basso, Jindrich Kopecky, Jakub Kucharz, Sebastiano Buti, Mimma Rizzo, Luca Galli, Thomas Büttner, Ugo De Giorgi, Ravindran Kanesvaran, Ondřej Fiala, Enrique Grande, Paolo Andrea Zucali, Giuseppe Fornarini, Maria T. Bourlon, Sarah Scagliarini, Javier Molina-Cerrillo, Gaetano Aurilio, Marc R. Matrana, Renate Pichler, Carlo Cattrini, Tomas Büchler, Emmanuel Seront, Fabio Calabrò, Alvaro Pinto, Rossana Berardi, Anca Zgura, Giulia Mammone, Jawaher Ansari, Francesco Atzori, Rita Chiari, Aristotelis Bamias, Orazio Caffo, Giuseppe Procopio, Maria Bassanelli, Sara Merler, Carlo Messina, Zsófia Küronya, Alessandra Mosca, Dipen Bhuva, Nuno Vau, Lorena Incorvaia, Sara Elena Rebuzzi, Giandomenico Roviello, Ignacio Ortego Zabalza, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Fernando Sabino M. Monteiro, Rodolfo Montironi, Nicola Battelli, Camillo Porta
ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
Michelle Wang, Shadera Slatter, Jesse Sussell, Chia-Wei Lin, Sarika Ogale, Debajyoti Datta, Atul J. Butte, Lyudmila Bazhenova, Vivek A. Rudrapatna
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study
Hélène Babey, Philippe Jamme, Hubert Curcio, Jean Baptiste Assié, Remi Veillon, Hélène Doubre, Maurice Pérol, Florian Guisier, Eric Huchot, Chantal Decroisette, Lionel Falchero, Romain Corre, Alexis Cortot, Christos Chouaïd, Renaud Descourt
Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis
Jonathan Heseltine, Jennifer Allison, Sam Wong, Kellati Prasad, Zhu-Chuen Oong, Helen Wong, Andrea Law, Natalie Charnley, Omi Parikh, Tom Waddell, Shien Chow
Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case–Control Study
Erica M. Storm, Dimitrios Makrakis, Genevieve I. Lin, Rafee Talukder, Dimitra R. Bakaloudi, Eshana E. Shah, Iris W. Liou, David Hockenbery, Petros Grivas, Ali Raza Khaki
Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours
Chih-Chieh Yen, Yu-Min Yeh, Hsuan-Yi Huang, Yu-Lin Ting, Pei-An Fu, Tzu-Chien Lin, I-Ting Liu, Chia-Jui Yen
Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer
Nan Zheng, Yimin Zhang, Yue Zeng, Qiang Ma, Ruiguang Zhang, Qian Zhao, Conghua Lu, Jie Tian, ZhiGuo Wang, Huan Tang, Nuo Luo, Hualiang Xiao, Yong He, Fang Wu, Li Li